Although immune checkpoint blockade regimens including cytotoxic T lymphocyte antigen 4 and programmed cell death 1 (PD-1) have been employed, they have not demonstrated a significant improvement in the survival time of GBM patients (13, 14). The gene discussed is PDCD1; the disease is glioblastoma.